Dr Reddy’s Laboratories announced on today that it has launched Sumatriptan Injection USP, Autoinjector System 6 mg/0.5 mL, for subcutaneous use in the US market on February 25.
It is a therapeutic equivalent generic version of IMITREX STATdose Pen® (sumatriptan succinate) 6 mg/0.5 mL. The product got approval from the United States Food & Drug Administration (USFDA), the Hyderabad-based pharma major said in a release.
Dr Reddy’s Sumatriptan Injection USP, Autoinjector System 6 mg/ 0.5 mL is available in a carton containing 2 single-dose prefilled syringes.
The IMITREX STATdose Pen brand and generic combined had U.S. sales of approximately $169 million for the most recent twelve months ending in December 2013 according to IMS Health.